M
Marc-Henri Stern
Researcher at Curie Institute
Publications - 196
Citations - 12240
Marc-Henri Stern is an academic researcher from Curie Institute. The author has contributed to research in topics: Gene & Breast cancer. The author has an hindex of 49, co-authored 168 publications receiving 9402 citations. Previous affiliations of Marc-Henri Stern include Necker-Enfants Malades Hospital & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Concurrent Olaparib with Radiotherapy in Patients with Triple Negative Breast Cancer: Final Results of the RADIOPARP Phase 1 Trial
Pierre Loap,Delphine Loirat,Frédérique Berger,Marjorie Monteiro Rodrigues,L. Bazire,J-Y Pierga,Anne Vincent-Salomon,Fatima Laki,Lotfi Boudali,Laurence Raizonville,Véronique Mosseri,Annette Jochem,M. Diallo,Marc-Henri Stern,Alain Fourquet,Y.M. Kirova +15 more
TL;DR: The RADIOPARP (NCT03109080) trial as discussed by the authors was a prospective phase I dose-escalation trial establishing the tolerance profile of Olaparib combined with breast radiotherapy in high-risk early TNBC patients.
Book ChapterDOI
ATM Gene Mutation Detection Techniques and Functional Analysis
Guillaume Rieunier,Guillaume Rieunier,Catherine Dubois d'Enghien,Alice Fiévet,Dorine Bellanger,Dominique Stoppa-Lyonnet,Marc-Henri Stern +6 more
TL;DR: Genetic and biochemical protocols currently used in the laboratory that have proven to be highly accurate, reproducible, and quantitative are presented.
Proceedings ArticleDOI
Abstract OT1-2-04: TP53 mutants in circulating tumor DNA and follow-up of BRCA1 mutation carriers: The CirCA01 study
François-Clément Bidard,Dominique Stoppa-Lyonnet,Catherine Noguès,Olivier Caron,Suzette Delaloge,Catherine Dugast,Christine Lasset,Frédérique Berger,Bernard Asselain,Olivier Lantz,Marc-Henri Stern,Jean-Yves Pierga +11 more
TL;DR: Correlation with patients outcome will allow to report whether TP53 ctDNA detection may be used as a new screening test that can be repeated easily in BRCA1-carriers with no evidence of tumor growth, and a new diagnostic test in B RCA1 -carriers who present a clinical or radiological abnormality.
Journal ArticleDOI
Lack of evidence for CDK12 as an ovarian cancer predisposing gene
Alexandre Eeckhoutte,Alexandre Eeckhoutte,Mathilde Saint-Ghislain,Mathilde Saint-Ghislain,Manon Reverdy,Manon Reverdy,Virginie Raynal,Sylvain Baulande,Guillaume Bataillon,Lisa Golmard,Dominique Stoppa-Lyonnet,Dominique Stoppa-Lyonnet,Tatiana Popova,Tatiana Popova,Claude Houdayer,Claude Houdayer,Elodie Manié,Elodie Manié,Marc-Henri Stern,Marc-Henri Stern +19 more
TL;DR: The lack of detection of deleterious variants and the observed proportion of missense variants in the series of ovarian carcinoma patients as compared with all human populations strongly suggests that CDK12 is not an ovarian cancer predisposing gene.
Journal ArticleDOI
Genomic Amplification Is Not a Frequent Event in Uveal Melanomas
Manuel Rodrigues,David Gentien,Marc-Henri Stern,Laurence Desjardins,Jérôme Couturier,Sarah L. Lake,Helen Kalirai,Andrew Dodson,Sarah E. Coupland,Bryony H. Lloyd,Bertil Damato,Azzam Taktak +11 more
TL;DR: This Correspondence relates to the article by Lake et al that reported copy number and genotyping analysis on formalin-fixed, paraffin-embedded samples using genome-wide SNP arrays version 6.0.